A5070594325- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Neuroblastoma Research and Treatments
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Neuroendocrine Tumor Research Advances
- Cancer Genomics and Diagnostics
- Pediatric Pain Management Techniques
- Pain Management and Opioid Use
- Cancer Immunotherapy and Biomarkers
- Hemophilia Treatment and Research
- Colorectal Cancer Treatments and Studies
- Pharmacovigilance and Adverse Drug Reactions
- Peptidase Inhibition and Analysis
- Medical Imaging Techniques and Applications
- Melanoma and MAPK Pathways
- Nausea and vomiting management
- Radiomics and Machine Learning in Medical Imaging
- Cancer survivorship and care
- Antibiotic Use and Resistance
- Antibiotics Pharmacokinetics and Efficacy
- Antimicrobial Resistance in Staphylococcus
- Pharmacological Effects and Toxicity Studies
- Drug-Induced Adverse Reactions
- Opioid Use Disorder Treatment
Vanderbilt University Medical Center
2020-2024
Vanderbilt University
2023
Preston University
2022
University of North Carolina Health Care
2021
University of North Carolina Hospitals
2018
University of North Carolina at Chapel Hill
2018
This study examined the pattern of use and factors predicting prolonged prescription opioid medications among cancer patients following treatment with curative intent.Patients diagnosed over a 3-year period at large urban safety-net hospital were included. Univariate multivariate analyses was used to identify associated continued use.Of 199 included in study, 38% receive an well beyond acute diagnosis phase. Mean age 60.3 years, female preponderance (63%). Surgical resection only (31.6%)...
In 2017, due to a fluid shortage secondary Hurricane Maria's devastation of Puerto Rico, hospitals and health-systems began substitute rolapitant for fosaprepitant as part chemotherapy-induced nausea vomiting prevention treatment strategies. However, despite advantageous pharmacologic formulation (e.g. long half-life, quicker time onset, lack first-pass hepatic metabolism) profiles, there seems be significant risk infusion-related hypersensitivity reactions associated with the administration...
Background: More than 50% of patients with lung cancer are admitted to the hospital while receiving treatment, which is a burden and healthcare system. This study characterizes risk factors outcomes who were hospital. Methods: A multidisciplinary oncology care team conducted retrospective medical record review in 2018. Demographics, disease admission characteristics, end-of-life utilization recorded. Following consensus process, admissions determined be either “avoidable” or “unavoidable.”...
Background: Tyrosine kinase inhibitors (TKIs) are the front-line therapy for chronic myeloid leukemia (CML), where phase 3 clinical trials have demonstrated their safety and efficacy. However, trial patients may not be representative of real-world (RWPs). Objective: To evaluate RWP factors associated with effectiveness in CML treated TKIs. Methods: Patients at least 30 days imatinib, dasatinib, nilotinib, or bosutinib between 2014 2018 were included. stratified into categories based on...
Whether influenza vaccination (FV) is associated with the severity of immune-related adverse events (IRAEs) in patients advanced thoracic cancer on immune checkpoint inhibitors (ICIs) not fully understood.Patients enrolled this retrospective cohort study were identified from Vanderbilt BioVU database and their medical records reviewed. Patients who received FV within 3 months prior to or during ICI treatment period FV-positive those did FV-negative cohort. The primary objective was detect...
lung cancer, lungs, NSCLC: NSCLCThe results of phase III eXalt3 trial were recently presented at the IASLC World Conference on Lung Cancer Presidential Symposium, revealing improved outcomes with first-line ensartinib over crizotinib in patients anaplastic lymphoma kinase (ALK)-rearranged non-small cell cancer (NSCLC). Ensartinib, a potent next-generation ALK tyrosine inhibitor (TKI), is new addition to treatment armamentarium this subtype NSCLC. The Evolution TKIs rearrangements, most...